Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImbruVeRCHOP in Elderly DLBCL
NCT03129828Phase 2Completed
- Start
- Mar 2017
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, bortezomib in diffuse large B-cell lymphoma (DLBCL). Started Mar 2017; status: completed.
02
Drugs
ibrutinibbortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03129828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03129828.